Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

British Journal of Cancer

Volumn 81, Issue 8, 1999, Pages 1304-1310

  Vanhoefer, U ^a   Muller M R ^a   Hilger, R A ^a   Lindtner, B ^a   Klaassen, U ^a   Schleucher, N ^a   Rustum, Y M ^b   Seeber, S ^a   Harstrick, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Multidrug resistance; Ovarian cancer; PAK 200S; Topotecan

Indexed keywords

DIHYDROPYRIDINE; DNA TOPOISOMERASE; GLYCOPROTEIN P; LACTONE; PAK 200S; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL LEVEL; CELL STRAIN MCF 7; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0032739648     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6694384     Document Type: Article

References (48)

1. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
2. Beijnen JH, Smith BR, Keijer WJ, van Gijn R, ten Bokkel Huinink WW, Vlasveld LT, Rodenhuis S and Underberg WJ (1990) High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864 A (NSC 609669) in plasma. J Pharm Biomed Anal 8: 789-795
3. Benedetti P, Fiorani P, Capuani L and Wang JC (1993) Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 53: 4343-4348
4. Chen AY and Liu LF (1994) DNA topoisomerase: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218
5. Chuman Y, Chen ZS, Sumizawa T, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, Yamada K, Akiyama S and Aikou T (1997) Reversal of MRP-associated drug resistance by the pyridine analogue, PAK-104P. Proc Am Assoc Cancer Res 38: 594 (abstract)
6. Covey JM, Jaxel C, Kohn KW and Pommier Y (1989) Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49: 5016-5022
7. Danks MK, Schmidt CA, Cirtain MC, Suttle P and Beck WT (1988) Altered catalytic activity of and DNA cleavable by DNA topoisomerase II from human leukemic cells selected for resistance to VM 26. Biochemistry 27: 8861-8869
8. D'Arpa P, Machlin PS, Ratrie H III, Rothfield NF, Cleveland DW and Earnshaw WC (1988) cDNA cloning or human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl terminal fragment. Proc Natl Acad Sci USA 85: 2543-2547
9. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP and Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemía with reduced topoisomerase I content. Mol Pharmacol 38: 471-480
10. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH and Goldsmith ME (1987) Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141-5148
11. Friedman HS, Dolan ME, Kaufmann SH, Colvin OM, Griffith OW, Moschel RC, Schold SC, Bigner DD and Ali-Osman F (1994) Elevated DNA polymerase α, DNA polymerase β, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res 54: 3487-3493
12. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC and Noc DA (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos Fate Biol Chem 20: 706-713
13. Gromova I, Kjeldsen E, Svejstrup JQ, Alsner Q. Christiansen K and Westergaard O (1993) Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res 21: 593-600
14. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
15. Hoki Y, Fujimori A and Pommier Y (1997) Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 40: 433-438
16. Holm C, Covey JM, Kerrigan D and Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365-6368
17. Hsiang Y-H and Lin LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
18. Hsiang Y-H, Lihou MG and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
19. Jansen WJM, Hulscher TM, Van Ark-Otte J, Giaccone G, Pinedo HM and Boven E (1998) CPT-II sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 77: 359-365
20. Jonsson E, Fridborg H, Csóka K, Dhar S, Sundström C, Nygren P and Larsson R (1997) Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76: 211-219
21. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF and Saijo N (1990) Establishment of a camptothecin analogue (CPT-II)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919-5924
22. Kapoor R, Slade DL, Fujimori A, Pommier Y and Harker WG (1995) Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 7: 83-95
23. Liu LF (1989) DNA topoisomerase poísons as antitumor drugs. Annu Rev Biochem 58: 351-375
24. Ma J, Malicpaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G and Schellens JHM (1998) Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 77: 1645-1652
25. Maliepaard M, Nooter K, Ma J, Loos WJ, Kolker HJ, Verweij J. Stoter G and Schellens JHM (1996) Relationship between P-glycoprotein, multidrug resistance-associated protein, and cellular accumulation of topoisomerase I inhibitors. Proc Am Assoc Cancer Res 37: 312 (abstract)
26. Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ and Kohn KW (1987) Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47: 2050-2055
27. Maltern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL and Johnson FL (1993) In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5: 467-474
28. Minderman H, Vanhoefer U, Toth K, Minderman MD and Rustum YM (1996) A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Cancer 78: 2428-2436
29. Müller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF and Seeber S (1994) Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis. Cytometry 15: 64-72
30. Niwa K, Yamada K, Furukawa T, Shudo N, Seto K, Matsumoto T, Takao S, Akiyama S and Shimazu H (1992) Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)-amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. Cancer Res 52: 3655-3660
31. Pommier Y (1996) Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 23 (suppl 3): 3-10
32. Rowinsky EK and Verweij J (1997) Review of phase I clinical studies with topotecan. Semin Oncol 24 (suppl 20): 3-10
33. Ryan AJ, Squires S, Strutt HL and Johnson RT (1991) Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19: 3295-3300
34. Ryan AJ, Squires S, Strutt HL, Evans A and Johnson RT (1994) Different fates of camptothecin-induced replication fork associated double-strand DNA breaks in mammalian cells. Carcinogenesis 15: 823-828
35. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107-1112
36. Slichenmeyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291
37. Sorenson M, Schested M and Jensen PB (1995) Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72: 399-404
38. Sugimoto Y, Tsukahara R, Oh-Hara T, Isoe T and Tsuruo T (1990a) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930.
39. Sugimoto Y, Tsukahara S, Oh-Hara T, Liu LF and Tsuruo T (1990b) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962-7965
40. Tan KB, Mattern MR, Eng WK, McCabe FL and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhihitors. J Natl Cancer Inst 81: 1732-1735
41. Trask DK, DiDonato JA and Muller MT (1984) Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO 3: 671-676.
42. Tsao YP, Russo A, Nyamuswa G, Silber R and Liu LF (1993) Interaction between replication forks and topoisomerase I DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53: 5908-5914
43. Twentyman PR, Wright KA and Blechen NM (1994) Modification by SDZ PSC-833 of sensitivity to etoposide, cisplatin and taxol in multidrug resistant (MDR) cells with P-glycoprotein (Pgp)-mediated and MRP-associated phenotypes. Ann Oncol 5 (Suppl 5): 153 (abstract)
44. Uemura T and Yanagida M (1984) Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO 3: 1734-1744
45. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML and Rustum YM (1996) PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2: 369-377
46. Vanhoefer U, Voigt W, Hilger RA, Yin MB, Harstrick A, Seeber S and Rustum YM (1997) Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13 (β-D-glucopyranosyl)-5H indolo[2,3 alpha]pyrrolo[3,4 c]carbazole-5,7(6H)-dione [NB-506], a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol Res 9: 485-494
47. Yang C-HJ, Horton JK, Cowan KH and Schneider E (1995) Cross-resistance to camptothecin analogues in a mitoxantrone resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55: 4004-4009
48. Yang L, Wold MS, Li JJ, Kelly TJ and Liu LF (1987) Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci USA 84: 950-954